Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventing physical and chemical degradation of the LABL-Fc-MOG<sub>R5</sub>, a bifunctional peptide inhibitor, with formulation development approaches.

Antibody therapeutics·2026
Same author

Selectively Targeting Leukemic MOLT-4 Cells by MTX-cIBR Conjugate: Mechanism of Action and Cellular Entry.

Life (Basel, Switzerland)·2026
Same author

Progress and challenges in drug delivery for the treatment of Alzheimer's disease.

Expert opinion on drug delivery·2026
Same author

Mislocalisation of FLT3-ITD receptor contributes to MV4-11 leukaemia cell resistance to antibody-drug conjugate.

Journal of enzyme inhibition and medicinal chemistry·2026
Same author

Investigating the impact of charge and hydrophilicity on peptide-mucin interactions using a simple mucin model.

AAPS open·2026
Same author

Targeting Hyaluronic Acid Increases Brain Retention of Intraventricular Dosed Antibodies in Mice.

Molecular pharmaceutics·2026

Related Experiment Video

Updated: Jun 9, 2026

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Peptide-mediated targeted drug delivery.

Sumit Majumdar1, Teruna J Siahaan

  • 1Department of Pharmaceutical Chemistry, The University of Kansas, Simons Research Laboratories, 2095 Constant Ave., Lawrence, Kansas, 66047, USA.

Medicinal Research Reviews
|September 4, 2010
PubMed
Summary

Targeted drug delivery using peptide conjugates offers a promising approach to treat diseases like cancer and autoimmune disorders. Understanding conjugate properties and cellular uptake mechanisms is key for effective therapeutic development.

More Related Videos

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers
10:12

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

Related Experiment Videos

Last Updated: Jun 9, 2026

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid
10:42

A Tripeptide-Stabilized Nanoemulsion of Oleic Acid

Published on: February 27, 2019

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers
10:12

Construction of Cyclic Cell-Penetrating Peptides for Enhanced Penetration of Biological Barriers

Published on: September 19, 2022

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Targeted drug delivery aims to enhance therapeutic efficacy and reduce side effects by directing drugs to specific cells.
  • Peptides, both linear and cyclic, are explored as targeting moieties due to their favorable synthesis, structural simplicity, and low immunogenicity.
  • Cell surface receptors like ICAM-1, LHRH, Bombesin, and LFA-1 are targeted by specific peptides for cellular binding and internalization.

Purpose of the Study:

  • To review the development of effective drug-peptide conjugates for targeted drug delivery.
  • To emphasize the chemistry and biology influencing the success of these conjugates.
  • To provide a guide for developing targeted delivery systems for cytotoxic drugs.

Main Methods:

  • Systematic analysis of physicochemical properties of drug-peptide conjugates.
  • Evaluation of receptor-mediated cellular internalization mechanisms.
  • Critical assessment of reported results for promising drug-peptide conjugates.

Main Results:

  • Peptides derived from cell surface proteins demonstrate potent binding affinity.
  • ICAM-1 receptor-derived peptides facilitate internalization into leukemic T-cells.
  • Physicochemical properties and internalization mechanisms are critical for successful targeting.

Conclusions:

  • Drug-peptide conjugates offer a viable strategy for selective cancer and autoimmune disease treatment.
  • Understanding conjugate chemistry and biology is essential for optimizing targeted delivery.
  • This review provides a framework for developing peptide-based targeted delivery of cytotoxic drugs.